Efficacy of low-dose methadone as an antitussive for patients with malignancy. A pilot study.

Phase 4

• Conditions: cough in malignancy; Respiratory - Other respiratory disorders / diseases; Cancer - Any cancer

• Registration Number: ACTRN12616001061426
• Lead Sponsor: Monash Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-08-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Screening ESAS (Edmonton Symptom Assessment Score administered as per standard Monash Supportive and Palliative Care Unit practice) of cough score of four or more
Able to give informed consent
English speaking
Malignancy requiring palliative care

Exclusion Criteria

Currently receiving systemic anticancer treatment including:
Any systemic cytotoxic chemotherapy or targeted therapy
Any radiotherapy to thorax within the past month
Known allergy or sensitivity to opioids
Any increase or commencement of corticosteroids within the last three days

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of patients with a clinically significant reduction in cough as evidenced by a drop in mean Leister Cough Quenstionnaire (LCQ) of 1.3 or in mean Cough Visual Analogue Scale (VAS) by 8 mm[Baseline, End of Day 3, Start of Day 5, end of Day 7];Proportion of participants with an improvement in Quality of life by drop on mean leister Cough Quenstionairre and Cough Visual analgoue scale[Baseline, End Day 3, Start Day 5, end Day 7]